Suven Life Sciences Ltd (Suven) has informed the exchanges that it has been granted a product patent from Singapore (11201507763R) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2033.
The granted claims of the patents include the class of selective 5-HT4 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson, and Schizophrenia.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and Phase 1 commenced SUVN-911.
In addition to these clinical compounds, the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.
Suven Life Sciences Ltd is currently trading at Rs 224.75, up by Rs 3.3 or 1.49% from its previous closing of Rs 221.45 on the BSE. The stock is currently trading above its 200 DMA.
Capitalstars Financial Research Private Limited is a research house and an investment advisory carrying out operations in the Indian Equities and Commodity market.We also provide a free trial to our client.Join our services and trade with us.
Also u can visit :-
capitalstars Quick payment
capitalstars past performance
Get more details here:-
Trading Tips
Stock Advisory Company
Financial Advisory company
Forex trading tips
0 comments:
Post a Comment